Avenue Therapeutics (ATXI) Misses Q1 EPS by 640c

Avenue Therapeutics (NASDAQ: ATXI) reported Q1 EPS of ($15.40), $6.40 worse than the analyst estimate of ($9.00).

For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Robinhood prices $2B convertible notes offering due 2029
• Sun Communities names Ileana McAlary as general counsel and EVP